<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37185240</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Gender differences in SLE: report from a cohort of 417 Caucasian patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000880</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000880</ELocationID><Abstract><AbstractText Label="BACKGROUND">SLE is an autoimmune disease that predominantly affects women. As most epidemiological and interventional studies are on populations with a clear female prevalence, the influence of gender in disease course, drug response and damage accrual is yet to be fully explored and comprehended.</AbstractText><AbstractText Label="OBJECTIVES">To describe gender differences in disease course, comorbidities, use of medications and long-term outcomes of a large cohort of patients with SLE.</AbstractText><AbstractText Label="METHODS">Retrospective gender-based analysis of prospectively collected data from a monocentric cohort of Caucasian patients with SLE with at least 1&#x2009;year of follow-up.</AbstractText><AbstractText Label="RESULTS">417 patients were included, 51 men and 366 women. Men displayed a significantly higher median age at disease onset and diagnosis and a higher prevalence of late-onset SLE, serositis at disease onset, antiphospholipid syndrome (APS) and use of mycophenolate within the first year of disease. Women had a higher prevalence of haematological abnormalities, a higher cumulative exposure to azathioprine and higher cumulative dose of glucocorticoids at 5 years. Male patients had a shorter time to first damage item and a higher prevalence of damage at 1 and 5 years, but this association was no longer significant when late-onset patients were excluded. No differences were found in prevalence of childhood onset, delay between onset and diagnosis, time to renal involvement and histology, cumulative autoantibody positivity, number of flares and hospitalisations, median SLE Damage Index score, type of damage, age and time to first cardiovascular event, chronic kidney disease and death.</AbstractText><AbstractText Label="CONCLUSIONS">In our cohort, clinical manifestations and disease course were similar in male and female patients; however, male patients displayed higher prevalence of APS and early damage accrual probably due to the later disease onset. These data highlight the importance of an intensive follow-up, prevention and treatment of complications in this category of patients, especially in the first years of disease.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trentin</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3661-6643</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Signorini</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cascarano</LastName><ForeName>Giancarlo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gualtieri</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilir&#xf2;</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valevich</LastName><ForeName>Anastasiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carli</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elefante</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0657-485X</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferro</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stagnaro</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucchi</LastName><ForeName>Dina</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-2161-2562</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnologies, University of Siena, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy chiaratani78@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosca</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Lupus Nephritis</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>13</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37185240</ArticleId><ArticleId IdType="pmc">PMC10151995</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000880</ArticleId><ArticleId IdType="pii">10/1/e000880</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pons-Estel GJ, Ugarte-Gil MF, Alarc&#xf3;n GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol 2017;13:799&#x2013;814. 10.1080/1744666X.2017.1327352</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2017.1327352</ArticleId><ArticleId IdType="pubmed">28471259</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Malik JM. Male lupus and the loch ness syndrome. Br J Rheumatol 1994;33:307&#x2013;8. 10.1093/rheumatology/33.4.307</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/33.4.307</ArticleId><ArticleId IdType="pubmed">8156300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu LJ, Wallace DJ, Ishimori ML, et al. . Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus 2010;19:119&#x2013;29. 10.1177/0961203309350755</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203309350755</ArticleId><ArticleId IdType="pmc">PMC7304291</ArticleId><ArticleId IdType="pubmed">19946032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 European League against rheumatism/american College of rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151&#x2013;9. 10.1136/annrheumdis-2018-214819</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538&#x2013;46. 10.1038/nrrheum.2010.121</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2010.121</ArticleId><ArticleId IdType="pubmed">20683438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovensk&#xfd; J, Tuchynov&#xe1; A. Systemic lupus erythematosus in the elderly. Autoimmun Rev 2008;7:235&#x2013;9. 10.1016/j.autrev.2007.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2007.11.014</ArticleId><ArticleId IdType="pubmed">18190884</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Petri MA, Kim MY, et al. . The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005;142(12 Pt 1):953&#x2013;62. 10.7326/0003-4819-142-12_part_1-200506210-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-142-12_part_1-200506210-00004</ArticleId><ArticleId IdType="pubmed">15968009</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Goldsmith CH, et al. . The reliability of the systemic lupus international collaborating clinics/american College of rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809&#x2013;13. 10.1002/art.1780400506</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400506</ArticleId><ArticleId IdType="pubmed">9153540</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho DE, Imai K, King G, et al. . matchit: nonparametric preprocessing for parametric causal inference. J Stat Soft 2011;42. 10.18637/jss.v042.i08</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v042.i08</ArticleId></ArticleIdList></Reference><Reference><Citation>Voulgari PV, Katsimbri P, Alamanos Y, et al. . Gender and age differences in systemic lupus erythematosus. A study of 489 Greek patients with a review of the literature. Lupus 2002;11:722&#x2013;9. 10.1191/0961203302lu253oa</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203302lu253oa</ArticleId><ArticleId IdType="pubmed">12475002</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervera R, Khamashta MA, Font J, et al. . Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. the european working party on systemic lupus erythematosus. Medicine (Baltimore) 1993;72:113&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8479324</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller MH, Urowitz MB, Gladman DD, et al. . Systemic lupus erythematosus in males. Medicine (Baltimore) 1983;62:327&#x2013;34. 10.1097/00005792-198309000-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-198309000-00005</ArticleId><ArticleId IdType="pubmed">6225928</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC, Boyd RE, Ahearn JM, et al. . Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 1985;64:285&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">2412088</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade RM, Alarc&#xf3;n GS, Fern&#xe1;ndez M, et al. . Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. results from a multiethnic US cohort. Arthritis Rheum 2007;56:622&#x2013;30. 10.1002/art.22375</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22375</ArticleId><ArticleId IdType="pubmed">17265497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, et al. . Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 2015;74:1706&#x2013;13. 10.1136/annrheumdis-2013-205171</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lau CS, Chan TM, et al. . Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus. Lupus 1999;8:188&#x2013;96. 10.1191/096120399678847605</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399678847605</ArticleId><ArticleId IdType="pubmed">10342711</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaharir SS, Kadir WDA, Nordin F, et al. . Systemic lupus erythematosus among male patients in Malaysia: how are we different from other geographical regions? Lupus 2019;28:137&#x2013;44. 10.1177/0961203318812676</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318812676</ArticleId><ArticleId IdType="pubmed">30458692</ArticleId></ArticleIdList></Reference><Reference><Citation>Leening MJG, Ferket BS, Steyerberg EW, et al. . Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ 2014;349:g5992. 10.1136/bmj.g5992</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g5992</ArticleId><ArticleId IdType="pmc">PMC4233917</ArticleId><ArticleId IdType="pubmed">25403476</ArticleId></ArticleIdList></Reference><Reference><Citation>Prevalence - general population. 2022. Available: https://www.cuore.iss.it/eng/indicators/cardiovascular_diseases</Citation></Reference><Reference><Citation>Ajeganova S, Hafstr&#xf6;m I, Frosteg&#xe5;rd J. Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years. Lupus Sci Med 2021;8:e000454. 10.1136/lupus-2020-000454</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2020-000454</ArticleId><ArticleId IdType="pmc">PMC7871345</ArticleId><ArticleId IdType="pubmed">33547230</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzi S, Selzer F, Sutton-Tyrrell K, et al. . Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51&#x2013;60. 10.1002/1529-0131(199901)42:1&lt;51::AID-ANR7&gt;3.0.CO;2-D</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199901)42:1&lt;51::AID-ANR7&gt;3.0.CO;2-D</ArticleId><ArticleId IdType="pubmed">9920014</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rn&#xe5;dal L, Yin L, Granath F, et al. . Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004;31:713&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15088296</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini M, Adami S, Bertoldo F, et al. . Guidelines for the diagnosis, prevention and management of osteoporosis. Reumatismo 2016;68:1&#x2013;39. 10.4081/reumatismo.2016.870</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2016.870</ArticleId><ArticleId IdType="pubmed">27339372</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernlund E, Svedbom A, Iverg&#xe5;rd M, et al. . Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 2013;8. 10.1007/s11657-013-0136-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-013-0136-1</ArticleId><ArticleId IdType="pmc">PMC3880487</ArticleId><ArticleId IdType="pubmed">24113837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bultink IEM. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:2&#x2013;8. 10.1002/acr.20568</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20568</ArticleId><ArticleId IdType="pubmed">22213721</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu C, Zhao R, Zhang X, et al. . A meta-analysis of secondary osteoporosis in systemic lupus erythematosus: prevalence and risk factors. Arch Osteoporos 2019;15:1. 10.1007/s11657-019-0667-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-019-0667-1</ArticleId><ArticleId IdType="pubmed">31802295</ArticleId></ArticleIdList></Reference><Reference><Citation>Compston J. Glucocorticoid-Induced osteoporosis: an update. Endocrine 2018;61:7&#x2013;16. 10.1007/s12020-018-1588-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-018-1588-2</ArticleId><ArticleId IdType="pmc">PMC5997116</ArticleId><ArticleId IdType="pubmed">29691807</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina JF, Drenkard C, Molina J, et al. . Systemic lupus erythematosus in males. A study of 107 Latin American patients. Medicine (Baltimore) 1996;75:124&#x2013;30. 10.1097/00005792-199605000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005792-199605000-00002</ArticleId><ArticleId IdType="pubmed">8965681</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan TC, Fang H, Magder LS, et al. . Differences between male and female systemic lupus erythematosus in a multiethnic population. J Rheumatol 2012;39:759&#x2013;69. 10.3899/jrheum.111061</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.111061</ArticleId><ArticleId IdType="pmc">PMC3605704</ArticleId><ArticleId IdType="pubmed">22382348</ArticleId></ArticleIdList></Reference><Reference><Citation>Binder SR, Litwin CM. Anti-Phospholipid antibodies and smoking: an overview. Clin Rev Allergy Immunol 2017;53:1&#x2013;13. 10.1007/s12016-016-8565-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-016-8565-4</ArticleId><ArticleId IdType="pubmed">27377297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>